menu
    • menu
    [{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Ducentis BioTherapeutics

    Menu

    Ducentis BioTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            LifeArc Portfolio Company Ducentis Bio Therapeutics Acquired by Arcutis Biotherapeutics for Up to $400 Million

                            Details : DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.

                            Brand Name : DS-234

                            Molecule Type : Large molecule

                            Upfront Cash : $16.0 million

                            September 08, 2022

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

                            Details : DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.

                            Brand Name : DS-234

                            Molecule Type : Large molecule

                            Upfront Cash : $16.0 million

                            September 07, 2022

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth